Please ensure Javascript is enabled for purposes of website accessibility

Why Alnylam Pharmaceuticals, Inc. Competed Higher Today

By Brian Orelli, PhD - May 26, 2016 at 3:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One biotech's bad luck is another biotech's good fortune.

What: Alnylam Pharmaceuticals (ALNY 1.65%) is up 11% at 3:15 p.m. EDT after Alnylam's competitor Ionis Pharmaceuticals (IONS 2.81%) disclosed that its partner GlaxoSmithKline (GSK 0.51%) won't start a phase 3 clinical trial for IONIS-TTRRx in patients with transthyretin (TTR)-related amyloid cardiomyopathy.

So what: Alnylam Pharmaceuticals also has a drug, revusiran, for TTR-amyloid cardiomyopathy. The drug is currently in phase 3 development that should finish enrolling in late 2016, putting a potential readout in mid-2018. GlaxoSmithKline plans to wait for data from a phase 3 trial Ionis Pharmaceuticals is running in a related disease called TTR-familial amyloid polyneuropathy that's scheduled to read out in the first half of next year, so Alnylam will have a substantial head start.

But it gets even better for Alnylam Pharmaceuticals. One of the reasons GlaxoSmithKline wants to wait is that Ionis Pharmaceuticals has observed thrombocytopenia, or low platelet levels, in patients with TTR-familial amyloid polyneuropathy treated with IONIS-TTRRx. Alnylam also has a drug, patisiran, to treat the polyneuropathy version of the disease.

We'll get phase 3 data from trials in the polyneuropathy version for both IONIS-TTRRx and patisiran next year. Assuming both drugs pass their pivotal trials, efficacy will be the main driver for sales, but if they produce similar results in patients, not having the risk of thrombocytopenia will give Alnylam an advantage. Low platelet levels is a manageable condition, but it's an added step for doctors to have to monitor, which they'd rather avoid if there's an equally good treatment that doesn't require it.

Now what: IONIS-TTRRx's side effect and related delay are clearly good news for Alnylam in terms of potential competition once revusiran and patisiran make it to market. However, the drugs still have to pass their phase 3 trials to get approved by regulators. Investors will get more information about the likelihood of success when Alnylam presents data from the phase 2 open-label extension trials for both drugs in July at the International Symposium on Amyloidosis.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
$148.25 (1.65%) $2.40
GSK Stock Quote
$43.75 (0.51%) $0.22
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
$38.06 (2.81%) $1.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.